EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Ohr Pharmaceutical, Inc. – OHRP

The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) resulting from allegations that Ohr Pharmaceutical may have issued materially misleading business information to the investing public.

On March 27, 2015, Ohr Pharmaceutical announced the results of a mid-stage study of its lead drug, OHR-102. The study was designed to determine whether the drug could be used in tandem with the existing treatment, injectable eye drug Lucentis, to reduce the number of Lucentis injections patients required. But Ohr announced that there was no “meaningful” reduction in the number of injections required when OHR-102 was used, and that its study had thus failed its primary endpoint. On this news, Ohr Pharmaceutical’s share price fell sharply during intraday trading on March 27, 2015.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Ohr Pharmaceutical investors. If you purchased shares of Ohr Pharmaceutical before March 27, 2015, please visit the website at http://rosenlegal.com/cases-561.html for more information. You may also contact Phillip Kim, Esq. or Jonathan Horne, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or jhorne@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.